Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 998 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cream Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion, Ultravate Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
13
States / cities
Rogers, Arkansas • Beverly Hills, California • Carlsbad, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 25, 2026, 4:07 PM EDT
Not listed Not applicable Interventional

Neuromodulation of Lidocaine Cream Effect on Chronic Pain Patients

NCT03046017
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
tDCS, Lidocaine cream, Control cream
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

NCT03958955
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Skokie, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

NCT05635838
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 25, 2026, 4:07 PM EDT
Not yet recruiting Phase 1 Interventional

Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

NCT07801248
View directory record Official record
Conditions
Acute Skin Graft Versus Host Disease (GVHD)
Interventions
Ruxolitinib 1.5% cream
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

NCT03826628
View directory record Official record
Conditions
Facial Angiofibroma, Tuberous Sclerosis
Interventions
rapamycin, placebo
Drug
Lead sponsor
Dermatology Specialties Limited Partnership
Industry
Eligibility
6 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

NCT00525499
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ASC-J9 cream, placebo
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

NCT02340234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Rectal USPE Measures

NCT02102867
View directory record Official record
Conditions
Microbicide Delivery System Perceptibility and Acceptability
Interventions
Gel, Cream, Liquid
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

NCT00821964
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Skin Metastases, Stage IV Breast Cancer
Interventions
imiquimod, Abraxane, laboratory biomarker analysis, RNA analysis, immunoenzyme technique
Drug · Other · Genetic
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 25, 2026, 4:07 PM EDT
Recruiting Phase 2 Interventional

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Delgocitinib cream, Vehicle cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Fountain Valley, California • Douglasville, Georgia • West Bloomfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin

NCT00276419
View directory record Official record
Conditions
Breast Pain, Non-cyclical Mastalgia, Surgical Scar-Related Breast Pain
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years

NCT01696799
View directory record Official record
Conditions
Interdigital Tinea Pedis
Interventions
Econazole Nitrate, placebo
Drug
Lead sponsor
AmDerma
Industry
Eligibility
12 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 4 Interventional

Vtama in Psoriasis Patients Being Treated With Biologics.

NCT06103695
View directory record Official record
Conditions
Psoriasis
Interventions
Tapinarof
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

Clubfoot Tenotomy Trial

NCT04766684
View directory record Official record
Conditions
Clubfoot
Interventions
Jet injection of 1% lidocaine, 4% liposomal lidocaine cream
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 6 Weeks
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

CeraVe Diabetes Mellitus

NCT04724967
View directory record Official record
Conditions
Diabetes Complications
Interventions
CeraVe Hydrating Cleanser, CeraVe Moisturizing Cream
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures

NCT01516684
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
placebo administration, EMLA, propofol, fentanyl citrate
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 22 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age

NCT00988533
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months to 3 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Bentonville, Arkansas • Dinuba, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 25, 2026, 4:07 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Combination Topical Therapy for Treatment of Scalp Actinic Keratoses

NCT03996252
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Calcipotriene 0.005% Foam, Efudex 5% Topical Cream
Drug
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 25, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Nu Skin Product, Cosmetic instrument, Tretinoin cream 0.05, CeraVe moisturizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 25, 2026, 4:07 PM EDT
Recruiting Early Phase 1 Interventional

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

NCT06645821
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
EVO101
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 25, 2026, 4:07 PM EDT